2021-01-06,MorphoSys Appoints Sung Lee as Chief Financial Officer
2020-12-17,MorphoSys AG: Corporate Calendar 2021
2020-12-07,Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
2020-12-07,Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
2020-12-02,DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)
2020-12-01,Thomas Biegi Joins MorphoSys As Head of Corporate Communications
2020-11-29,Where Do Hedge Funds Stand On MorphoSys AG (MOR)?
2020-11-12,MorphoSys AG (MOR) Q3 2020 Earnings Call Transcript
2020-11-12,MorphoSys AG to Host Earnings Call
2020-11-12,"Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal"
2020-11-11,MorphoSys Reports Nine Months and Third Quarter 2020 Results
2020-11-11,MorphoSys and Cherry Biolabs Announce Licensing of Hemibody Technology
2020-11-11,"Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab"
2020-11-05,"Incyte (INCY) Q3 Earnings & Sales Miss, Jakafi Demand Strong"
2020-11-04,MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition
2020-11-04,"Invitation to MorphoSys' Third Quarter and First 9-Month 2020 Results Conference Call on November 12, 2020"
2020-10-27,MorphoSys AG Raises its Financial Guidance for the Full Year 2020
2020-10-19,MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)
2020-10-13,MorphoSys AG Successfully Places EUR 325 Million Convertible Bonds
2020-10-13,MorphoSys AG Launches an Offering of Approx. EUR 325 Million Convertible Bonds
2020-09-30,"MorphoSys Announces Departure of Jens Holstein, CFO, by Year End 2020"
2020-09-17,MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
2020-09-17,MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
2020-09-17,Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
2020-08-18,National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
2020-08-18,National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
2020-08-05,MorphoSys Reports Second Quarter and First Half 2020 Results
2020-08-03,"Incyte, MorphoSys Win FDA Nod For Key Revenue Driver Tafasitamab"
2020-07-31,FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2020-07-31,MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2020-07-31,FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2020-07-30,"Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020"
2020-07-15,"MORNING BID-Fog, stall ... rally"
2020-07-14,MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis
2020-06-10,MorphoSys AG (MOR): Are Hedge Funds Right About This Stock?
2020-06-10,Anti-inflammatory and cancer drugs tested in UK as possible COVID-19 therapy
2020-06-09,GSK begins U.S. test of experimental drug for pneumonia from COVID-19
2020-06-05,AstraZeneca blood cancer drug shows signs of helping COVID-19 patients
2020-06-02,MorphoSys to Present at Upcoming Virtual Investor Conferences
2020-05-27,MorphoSys AG Reports Outcome of Annual General Meeting 2020
2020-05-21,"Incyte, MorphoSys Application for Lymphoma Drug Validated"
2020-05-20,MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab
2020-05-14,MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings
2020-05-14,MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL
2020-05-09,MorphoSys AG (MOR) Q1 2020 Earnings Call Transcript
2020-05-09,Do Its Financials Have Any Role To Play In Driving MorphoSys AG's (ETR:MOR) Stock Up Recently?
2020-05-06,MorphoSys Reports First Quarter 2020 Results
2020-04-30,"Invitation to MorphoSys' First Quarter 2020 Results Conference Call on May 7, 2020"
2020-04-28,Axsome Shares Jump 25% on Alzheimer's Study Results
2020-04-27,MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland China
2020-04-27,I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
2020-04-21,"MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer"
2020-04-06,Is MorphoSys AG (MOR) Going to Burn These Hedge Funds?
2020-04-06,MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures
2020-04-06,MorphoSys says coronavirus impacting clinical studies and business
2020-03-19,MorphoSys AG to Host Earnings Call
2020-03-18,MorphoSys Presents Results for Fiscal Year 2019
2020-03-12,"Invitation to MorphoSys' Year-End Results 2019 Conference Call on March 19, 2020"
2020-03-05,Incyte approval triggers $750M payment for drug collaboration
2020-03-04,"MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,629,764 American Depositary Shares by Incyte Corporation"
2020-03-03,MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab
2020-03-02,MorphoSys BLA for Cancer Drug Gets Priority Review from FDA
2020-03-02,FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL
2020-02-04,MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
2020-01-14,MorphoSys AG's (ETR:MOR) Path To Profitability
2020-01-13,"MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab"
2019-12-30,MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
2019-12-27,First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL
2019-12-22,Is MorphoSys AG (MOR) A Good Stock To Buy?
2019-12-12,MorphoSys AG: Corporate Calendar 2020
2019-11-21,Chief scientist quits at Germany's Morphosys ahead of product launch
2019-11-20,"Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure"
2019-11-18,MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
2019-11-15,MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice
2019-11-14,MorphoSys (ETR:MOR) Shareholders Have Enjoyed An Impressive 116% Share Price Gain
2019-11-11,Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner
2019-11-06,MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting
2019-10-29,MorphoSys AG Reports Third Quarter 2019 Financial Results
2019-10-29,MorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone
2019-10-29,MorphoSys AG: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone
2019-10-29,"The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study"
2019-10-28,MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
2019-10-28,MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped
2019-10-23,Did Hedge Funds Drop The Ball On MorphoSys AG (MOR) ?
2019-10-21,"Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019"
2019-10-14,MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China
2019-09-18,MorphoSys to Present at Upcoming Investor Conferences
2019-09-16,MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis
2019-08-07,MorphoSys AG (MOR) Q2 2019 Earnings Call Transcript
2019-08-06,MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL
2019-08-06,MorphoSys AG Reports Second Quarter 2019 Financial Results
2019-08-06,MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency
2019-07-25,"Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019"
2019-07-08,MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology
2019-07-03,MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
2019-07-03,Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
2019-06-25,"CORRECTION: Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer"
2019-06-24,"UPDATE 2-European shares fall as Daimler weighs, Sino-U.S. trade news awaited"
2019-05-15,MorphoSys AG (MOR) Q1 2019 Earnings Call Transcript
2019-05-08,MorphoSys AG to Host Earnings Call
